TMO — Thermo Fisher Scientific Cashflow Statement
0.000.00%
Last trade - 00:00
- $215.76bn
- $242.70bn
- $42.86bn
- 83
- 18
- 69
- 58
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 3,696 | 6,375 | 7,728 | 6,960 | 5,955 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | -33 | 536 | 1,187 | 857 | 882 |
Discontinued Operations | |||||
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -665 | -395 | -1,548 | -1,049 | -537 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | 4,973 | 8,289 | 9,312 | 9,154 | 8,406 |
Capital Expenditures | -926 | -1,474 | -2,523 | -2,243 | -1,479 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -561 | -36 | -19,409 | 84 | -3,663 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -1,487 | -1,510 | -21,932 | -2,159 | -5,142 |
Financing Cash Flow Items | -69 | -147 | -91 | -9 | 56 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -3,118 | 959 | 6,581 | -2,810 | -3,622 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 305 | 7,914 | -5,845 | 4,046 | -440 |